Eyestem, a Bangalore based biotech startup, is revolutionizing the field of cell therapy with its mission to develop scalable, accessible treatments for incurable diseases.
The company is spearheaded by a team of experts in clinical trials, cell therapy, and ophthalmology and aims to democratize therapies for the bottom 99% of the global population.
Vision for Scalable Innovation
Eyestem’s long-term goal is to create a robust platform for scalable cell therapies targeting a range of incurable diseases.
This innovative platform integrates manufacturing and quality processes designed to streamline the pathway from research to market, ensuring that life-saving treatments are accessible worldwide.
The company’s lead product, Eyecyte-RPETM, is focused on treating Dry Age-related Macular Degeneration (AMD), a condition that affects over 170 million people globally and is the leading cause of blindness in individuals over 60.
Pioneering Solutions for Dry AMD
Dry AMD, which currently has no available treatment, is at the forefront of Eyestem’s research.
Eyecyte-RPETM is an allogeneic product that replaces lost retinal pigment epithelium (RPE) cells in the retina.
Clinical trials for this breakthrough therapy are set to begin in 2024 at Oregon Health and Science University, with hopes to arrest vision loss and restore sight for millions.
Eyestem is one of only six companies globally developing this solution.
Expanding Product Pipeline
Eyestem’s innovations extend beyond AMD. The company is developing Eyecyte-PRP to replace lost photoreceptor cells for treating Retinitis Pigmentosa, a rare inherited retinal disorder.
Additionally, Aircyte-AEC, a potential treatment for Idiopathic Pulmonary Fibrosis, is in advanced development stages and targets lung restoration through intra-bronchial inhalation therapies.
Leading the Way in Affordable Therapies
With the global market for cell therapies in diseases like Dry AMD ($72 billion) and Retinitis Pigmentosa ($10 billion) rapidly growing, Eyestem aims to capture a significant market share while maintaining affordability.
The company’s bold approach seeks to position it as the industry benchmark for both quality and accessibility in the field of cell therapy.
About Eyestem
Founded by Dr. Jogin Desai, Dr. Rajani Battu, Dr. Rajarshi Pal, and Dr. Dhruv Sareen, Eyestem combines decades of expertise in stem cell research, ophthalmology, and clinical innovation.
With a strong focus on bringing transformative therapies to underserved populations, Eyestem continues to push the boundaries of science in pursuit of global healthcare solutions.
